30 August 2024
30 August 2024
Available from 30 August 2024, the update introduces three new assays to address specific research needs.
The FemVue MINI device offers the same efficacy as the original FemVue but in a more environmentally friendly package.
Kiyatec’s technology tests a patients’ cancer cells with chemotherapy to see how well they will respond to standard-of-care treatment.
US-based research body, the Sage Group is calling on the global medical device industry to advance treatments for neglected indications of below-the-ankle (BTA) disease in critical limb ischemia (CLI).
The eyonis LCS SaMD is designed to enhance the detection and diagnostic accuracy of LDCT for lung cancer screening.
The Vertex system utilises the Endoportal Control technology to enhance precision in catheter-based interventions.
The company plans to kick start device commercialisation later this year following the FDA’s regulatory greenlight.
After two reports cast doubt on the effectiveness of the spinal cord stimulators for the treatment of pain, the Australian health authorities have suspended the devices from sale.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
